Interferon gamma-inducible protein 16 in primary Sjögren’s syndrome: a novel player in disease pathogenesis?

Table 1 Demographic, clinical and serological characteristics of pSS patients

	All pSS	IFI16 neg	IFI16 pos	p	anti-IFI16 neg	anti-IFI16 pos	p
Patient number (n)	67	53	14	–	44	23	–
Age (years)^a	59 ± 1	60 ± 2	55 ± 3	0.2	60 ± 2	56 ± 2	0.2
Age at diagnosis (years)^a	49 ± 2	50 ± 2	45 ± 3	0.3	51 ± 2	46 ± 2	0.3
Disease duration (years)^a	9 ± 1	9 ± 1	10 ± 1	0.1	9 ± 1	10 ± 2	0.1
Xerophtalmia	92.5	94.3	85.7	0.3	86.4	82.6	0.7
Xerostomia	85.1	88.7	71.4	0.2	90.9	95.7	0.6
Salivary gland swelling	47.8	49.1	42.9	0.8	50.0	43.5	0.8
Extraglandular manifestations^b	76.1	77.3	71.4	0.7	79.5	69.5	0.4
Leukopenia	37.3	37.7	35.7	0.9	38.6	34.8	0.8
Hypergammaglobulinemia	61.2	56.6	78.6	0.2	61.4	60.9	0.8
Hypocomplementemia	26.9	22.6	42.9	0.2	25.0	30.4	0.7
Autoantibodies
Neither anti-SSA nor anti-SSB	16.4	17.0	14.3	0.9	18.2	13	0.7
Anti-SSA only	26.9	28.3	21.4	0.7	20.5	39.1	0.1
Anti-SSA and anti-SSB	56.7	54.7	64.3	0.6	61.4	47.8	0.3
RF ± anti-SSA ± anti-SSB	68.7	60.4	100	0.003	70.5	65.2	0.8

^aValues are reported as mean ± standard error of the mean and corresponding p values are calculated with Mann Whitney U test. All other values are reported as percentage of patients and corresponding p values are calculated with chi square test. ^bPercentage of patients with at least one extraglandular manifestation including articular, pulmonary or esophageal involvement, purpura, Raynaud’s phenomenon and lymphadenopathy. IFI16 interferon gamma-inducible protein 16, neg negative, pos positive, pSS primary Sjögren’s syndrome, RF rheumatoid factor

ISSN: 1478-6362